drugset / Trial / NCT02999295
A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer
Phase 1/2
Completed
46 enrolled
National Cancer Center, Japan
Fiverings Co., Ltd. · collabOno Pharmaceutical Co., Ltd. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The main purpose of this study is to evaluate the safety and efficacy of the combination therapy of ramucirumab and nivolumab in participants with advanced or recurrent unresectable gastric or GEJ cancer.
Timeline
- Start
- 2017-01
- Primary completion
- 2017-11
- Completion
- 2019-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 1 mg/kg | — |
| Subject | Nivolumab | Monoclonal antibody | 3 mg/kg | — |
| Subject | Ramucirumab | Monoclonal antibody | 8 mg/kg | — |